Should I buy Fisher & Paykel or ResMed shares?

Let's see which of these two names could be best buys.

| More on:
A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors looking for exposure to the growing field of respiratory healthcare and sleep apnoea treatment may find themselves comparing two ASX-listed giants: Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) and ResMed Inc. (ASX: RMD).

Both companies are global leaders with strong track records, but when it comes to deciding which to buy today, the case for ResMed shares looks particularly compelling.

Fisher & Paykel

Fisher & Paykel is a New Zealand-based medical device company that designs, manufactures and markets equipment used in acute and chronic respiratory care, surgical applications, and sleep apnoea treatment.

The company has a presence in more than 120 countries and has built a strong reputation over decades. However, despite the quality of the business, analysts are taking a more measured view for now.

Morgan Stanley currently has an equal-weight (hold) rating on the stock with a $36.30 price target, compared to its recent share price of $31.40. That represents some upside, but the broker isn't quite ready to call it a buy.

ResMed Inc

ResMed, on the other hand, continues to win fans among analysts — and for good reason.

The company is the world's leading manufacturer of CPAP devices and masks for the treatment of Obstructive Sleep Apnea (OSA), a condition that is still significantly underdiagnosed. With rising awareness and greater access to sleep health services, this market is poised for long-term growth.

Goldman Sachs recently reaffirmed its conviction buy rating on ResMed shares with a $49.00 price target, well above the current share price of $33.82.

Goldman's bullish thesis rests on three pillars: Strong CPAP patient growth driven by increasing awareness of OSA. Market share gains, with ResMed already holding the #1 position globally. And margin expansion, supported by a favourable product mix and better cost efficiency.

The broker is forecasting around 10% annual revenue growth and 15% annual earnings growth through FY 2027 — a powerful combination for long-term investors.

Goldman also notes that ResMed's valuation remains attractive, with its trading multiple below its 10-year average, offering room for a potential re-rating as earnings momentum builds.

So, which one should you buy?

While Fisher & Paykel remains a high-quality healthcare business, analysts appear more cautious on its near-term outlook. ResMed, in contrast, looks well-positioned to benefit from secular growth trends, market leadership, and improving profitability — and it is trading well below its recent highs.

For investors looking for growth, value, and global exposure to a major healthcare trend, ResMed shares might just be the better pick right now.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »